Aurinia Pharmaceuticals share price logo

Aurinia Pharmaceuticals

NASDAQ: AUPH

Mid Cap

$15.83

-0.12

(-0.75%)

as on

Aurinia Pharmaceuticals Stock Performance

as on October 3, 2026 at 2:16 pm IST

  • Day's Low

    Day's High

    $15.74
    $16.06
    downward going graph

    0.57%

    Downside

    1.45%

    Upside

    downward going graph
  • 52 Week's Low

    52 Week's High

    $10.90
    $19.25
    downward going graph

    31.13%

    Downside

    21.60%

    Upside

    downward going graph

Aurinia Pharmaceuticals share price movements today

Previous Close
$15.95
Open
$16.00
Volume
671.2K
Market Cap
$2.1B
Day's Low - High
$15.74 - $16.06
52 Week Low - High
$10.90 - $19.25

Aurinia Pharmaceuticals Historical Returns

1 Month Return
-1.8 %
3 Month Return
+ 1.41 %
1 Year Return
+ 39.47 %
3 Year Return
+ 117.15 %
5 Year Return
-27.42 %

Aurinia Pharmaceuticals Stock Fundamentals & Key Indicators

Check Aurinia Pharmaceuticals market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.

Market Cap

$2.1B

EPS (TTM)

2.36

Dividend Yield

0.00%

Quarterly Earnings Growth YOY

0.76%

PE Ratio (TTM)

6.81

Industry PE ratio

-12.07

PEG Ratio

0.02

EBITDA

188.2M

Revenue (TTM)

311.5M

Profit Margin

90.36%

Return On Equity TTM

59.00%

Aurinia Pharmaceuticals vs Peer Comparison

Compare market cap, revenue, PE, and other key metrics of Aurinia Pharmaceuticals with its industry peers.

Company
Analyst View
Market Cap
5 Years Return %PE RatioProfit Margin %Dividend Yield %
Buy$2.1B-27.42%6.8190.36%0.00%
StrongBuy$44.1B609.62%-23.340.00%0.00%
Neutral$75.4B-44.29%-24.08-12.57%0.00%
StrongBuy$132.5B180.98%30.1986.04%0.00%
Buy$78.1B28.80%17.6784.86%0.50%

Stock Returns calculator for Aurinia Pharmaceuticals Stock including INR - Dollar returns

The Aurinia Pharmaceuticals stock calculator helps Indian investors calculate returns based on the historical performance of the stock. Just choose your investment amount and duration to get insights and invest more confidently. See stock returns as well as the effect of dollar appreciation over different durations.

*Dollar Impact: The bonus return you make when the US Dollar rises against the Rupee; calculated on the full amount you walk away with, not just what you invested in.

Investment Value

₹1,00,000

  • 1Y

  • 3Y

  • 5Y

  • 7Y

  • 10Y

Aurinia Pharmaceuticals investment value today

Current value as on today

₹1,51,387

Returns

₹51,387

(+51.39%)

Returns from Aurinia Pharmaceuticals Stock

₹39,471 (+39.47%)

Dollar Impact

₹11,916 (+11.92%)

Analyst Recommendation on Aurinia Pharmaceuticals Stock

Based on 3 analysts

BUY

66.67%

Buy

33.33%

Hold

0.00%

Sell

Based on 3 analysts, 66.66666666666666% of analysts recommend a 'BUY' rating for Aurinia Pharmaceuticals. Average target price of $17.86

Aurinia Pharmaceuticals Share Price Target

Get share price movements and forecasts by analysts on Aurinia Pharmaceuticals.

What analysts predicted

11.37%UPSIDE

Target Price

$17.86

Current Price

$15.83

Analyzed by

3 Analysts

High

$21

Target

$17.86

Low

$16

Aurinia Pharmaceuticals target price $17.86, a slight upside of 11.37% compared to current price of $15.83. According to 3 analysts rating.

Indian Investors' Interest in Aurinia Pharmaceuticals Stock

Search interest for Aurinia Pharmaceuticals Stock has decreased by -34% in the last 30 days, reflecting a downward trend in search activity.

Time period: to

Change:-34% versus previous 30 day period

Aurinia Pharmaceuticals Quarterly Profit & Loss

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Total Revenue
50
57
67
59
62
70
73
77
77
83
Gross Profit
42
48
61
54
53
62
64
68
71
76
Operating Income
-10
-1
11
-1
21
20
29
33
41
46
EBITDA
-3
7
20
7
30
28
36
47
49
54
Interest Expense
1
1
1
1
1
1
-
6
1
0
Depreciation
4
4
4
4
4
4
4
4
4
4
Income Before Tax
-10
1
14
1
24
22
31
35
43
48
Income Tax Expense
0
0
0
0
1
0
0
-175
9
11
Net Income
-10
0
14
1
23
21
31
210
34
37
Net Profit Margin
84.59%
84.42%
91.10%
90.73%
86.27%
89.84%
88.42%
89.01%
91.63%
92.12%

Aurinia Pharmaceuticals Annual Profit & Loss

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Total Revenue
0
0
0
50
45
134
175
235
283
Gross Profit
0
-40
0
50
44
128
161
206
250
Operating Income
-47
-56
-90
-104
-180
-111
-91
-4
104
EBITDA
-45
-53
-89
-102
-177
-103
-63
31
127
Interest Expense
-
-
-
-
-
-
2
4
4
Depreciation
1
1
1
1
2
2
11
19
9
Income Before Tax
-70
-64
-88
-102
-180
-106
-77
7
114
Income Tax Expense
-
0
0
0
0
1
0
1
-173
Net Income
-70
-64
-88
-102
-180
-108
-78
5
287
Net Profit Margin
99.76%
-8837.80%
100.00%
100.00%
97.61%
95.77%
91.94%
87.99%
88.46%

Aurinia Pharmaceuticals Quarterly Cash Flow

All numbers in Millions USD

Mar 2024
Jun 2024
Sep 2024
Dec 2024
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Jun 2026
Net Income
-10
0
14
1
23
21
31
210
34
37
Operating Cash Flow
-18
15
17
30
1
44
44
44
32
52
Investing Cash Flow
49
-38
-10
39
31
-13
-13
-36
-18
81
Financing Cash Flow
-15
-8
-2
-23
-49
-44
-10
0
-53
5
Change in Cash
15
-31
3
46
-17
-13
20
7
-39
138

Aurinia Pharmaceuticals Annual Cash Flow

All numbers in Millions USD

Dec 2017
Dec 2018
Dec 2019
Dec 2020
Dec 2021
Dec 2022
Dec 2023
Dec 2024
Dec 2025
Net Income
-70
-64
-88
-102
-180
-108
-78
5
287
Operating Cash Flow
-41
-51
-63
-69
-157
-79
-33
44
135
Investing Cash Flow
-8
0
7
-158
-103
-60
-6
39
-32
Financing Cash Flow
175
4
243
194
221
2
-5
-49
-106
Change in Cash
125
-47
188
-33
-40
-137
-45
34
-3

Global Institutional Holdings in Aurinia Pharmaceuticals

Check out the Institutions with significant holdings in Aurinia Pharmaceuticals.

Funds
Holdings
iShares
4.46%
TIAA-CREF Funds
1.40%
Fidelity Salem Street Trust
0.95%
Vanguard
0.95%
VANGUARD SCOTTSDALE FUNDS
0.53%

Aurinia Pharmaceuticals News & Key Events

  • img

    Today's Timeline - 15 October

    Wed, 04:13 PM

    -

    Aurinia Pharmaceuticals to present new LUPKYNIS data at ACR and ASN conferences, enhancing understanding of lupus nephritis treatment.

Insights on Aurinia Pharmaceuticals

Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.

  • imgPOSITIVE IMPACT

    Price Rise

    img

    In the last 1 year, AUPH stock has moved up by 39.5%

  • imgPOSITIVE IMPACT

    Revenue Rich

    img

    Revenue is up for the last 7 quarters, 59.86M → 83.22M (in $), with an average increase of 5.3% per quarter

  • imgPOSITIVE IMPACT

    Best in 3 Years

    img

    In the last 3 years, AUPH has outperformed top 5 stocks with highest market-cap in its industry

  • imgPOSITIVE IMPACT

    Profit Spike

    img

    Netprofit is up for the last 2 quarters, 34.35M → 37.41M (in $), with an average increase of 8.2% per quarter

  • imgNO EFFECT

    Against Peers

    img

    In the last 1 year, Moderna, Inc. Common Stock has given 566.9% return, outperforming this stock by 527.4%

About Aurinia Pharmaceuticals

Aurinia Pharmaceuticals Inc. operates as a commercial-stage biopharmaceutical company, specializing in the development and commercialization of innovative therapies. Its core mission is to address a variety of diseases for which current medical solutions are inadequate, serving patient populations across the United States and internationally. The company's flagship product is LUPKYNIS, an approved treatment designed for adult individuals suffering from active lupus nephritis. Furthermore, Aurinia maintains a strategic collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. The firm's main corporate office is located in Victoria, Canada.
OrganisationAurinia Pharmaceuticals
Headquarters#140, 14315 – 118 Avenue, Edmonton, AB, T5L 4S6, CA
IndustryBiotechnology
CEOKevin C. Tang

Key Management of Aurinia Pharmaceuticals

Name

Title

Mr. Peter S. Greenleaf M.B.A.

Consultant

Mr. Michael S. Hearne CPA

Chief Financial Officer

Mr. Ryan Cole

Chief Operating Officer

Mr. Thomas Wei

Chief Scientific Officer

Mr. Stewart M. Kroll

Chief Development Officer

Mr. Kevin C. Tang

Chairman & CEO

Mr. Stephen P. Robertson

Chief Legal Officer, Corporate Secretary & Chief Compliance Officer

FAQs

What is Aurinia Pharmaceuticals share price today?

Aurinia Pharmaceuticals share price today is $15.83 as on at the close of the market. Aurinia Pharmaceuticals share today touched a day high of $16.06 and a low of $15.74.

What is the 52 week high and 52 week low for Aurinia Pharmaceuticals share?

Aurinia Pharmaceuticals share touched a 52 week high of $19.25 on and a 52 week low of $10.90 on . Aurinia Pharmaceuticals stock price today i.e. is closed at $15.83,which is 17.77% down from its 52 week high and 45.21% up from its 52 week low.

What is Aurinia Pharmaceuticals's market capitalisation today?

Aurinia Pharmaceuticals market capitalisation is $0.00T as on .

How to invest in Aurinia Pharmaceuticals Stock (AUPH) from India?

  1. Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
  2. Step 2: Search for Aurinia Pharmaceuticals on INDmoney app. Click on Buy button.

What is the minimum amount required to buy Aurinia Pharmaceuticals Stock (AUPH) from India?

Indian investors can start investing in Aurinia Pharmaceuticals (AUPH) shares with as little as ₹96.300003051758 or $1 (as of ) using the INDmoney app.
For example: If you want to invest $10 or ₹963.00 in Aurinia Pharmaceuticals stock (as per the Rupee-Dollar exchange rate as on ). Based on Aurinia Pharmaceuticals share’s latest price of $15.83 as on October 3, 2026 at 8:46 am IST, you will get 0.6317 shares of Aurinia Pharmaceuticals. Learn more about fractional shares .

What are the returns that Aurinia Pharmaceuticals has given to Indian investors in the last 5 years?

Aurinia Pharmaceuticals stock has given -27.42% share price returns and 28.69% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?